全文获取类型
收费全文 | 345349篇 |
免费 | 25269篇 |
国内免费 | 8669篇 |
专业分类
耳鼻咽喉 | 2761篇 |
儿科学 | 5702篇 |
妇产科学 | 5129篇 |
基础医学 | 33872篇 |
口腔科学 | 6980篇 |
临床医学 | 33409篇 |
内科学 | 49276篇 |
皮肤病学 | 4966篇 |
神经病学 | 20969篇 |
特种医学 | 11854篇 |
外国民族医学 | 42篇 |
外科学 | 32710篇 |
综合类 | 48037篇 |
现状与发展 | 46篇 |
一般理论 | 10篇 |
预防医学 | 22550篇 |
眼科学 | 6926篇 |
药学 | 39511篇 |
160篇 | |
中国医学 | 24413篇 |
肿瘤学 | 29964篇 |
出版年
2024年 | 673篇 |
2023年 | 5098篇 |
2022年 | 10407篇 |
2021年 | 14432篇 |
2020年 | 12637篇 |
2019年 | 11873篇 |
2018年 | 11730篇 |
2017年 | 12737篇 |
2016年 | 13071篇 |
2015年 | 12348篇 |
2014年 | 18597篇 |
2013年 | 25288篇 |
2012年 | 18281篇 |
2011年 | 20950篇 |
2010年 | 15054篇 |
2009年 | 14606篇 |
2008年 | 16034篇 |
2007年 | 17401篇 |
2006年 | 16053篇 |
2005年 | 14531篇 |
2004年 | 12289篇 |
2003年 | 10941篇 |
2002年 | 8849篇 |
2001年 | 7992篇 |
2000年 | 6596篇 |
1999年 | 5550篇 |
1998年 | 4507篇 |
1997年 | 4403篇 |
1996年 | 3865篇 |
1995年 | 3477篇 |
1994年 | 3168篇 |
1993年 | 2605篇 |
1992年 | 2443篇 |
1991年 | 2268篇 |
1990年 | 1971篇 |
1989年 | 1662篇 |
1988年 | 1627篇 |
1987年 | 1464篇 |
1986年 | 1302篇 |
1985年 | 1767篇 |
1984年 | 1488篇 |
1983年 | 1068篇 |
1982年 | 1162篇 |
1981年 | 974篇 |
1980年 | 903篇 |
1979年 | 753篇 |
1978年 | 499篇 |
1977年 | 379篇 |
1976年 | 368篇 |
1975年 | 264篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
Xiying Fan Glen A. Bjerke Kent Riemondy Li Wang Rui Yi 《Molecular carcinogenesis》2019,58(12):2241-2253
MicroRNAs (miRNAs) play important roles in prostate cancer development. However, it remains unclear how individual miRNAs contribute to the initiation and progression of prostate cancer. Here we show that a basal layer‐enriched miRNA is required for prostate tumorigenesis. We identify miR‐205 as the most highly expressed miRNA and enriched in the basal cells of the prostate. Although miR‐205 is not required for normal prostate development and homeostasis, genetic deletion of miR‐205 in a Pten null tumor model significantly compromises tumor progression and does not promote metastasis. In Pten null basal cells, loss of miR‐205 attenuates pAkt levels and promotes cellular senescence. Furthermore, although overexpression of miR‐205 in prostate cancer cells with luminal phenotypes inhibits cell growth in both human and mouse, miR‐205 has a minimal effect on the growth of a normal human prostate cell line. Taken together, we have provided genetic evidence for a requirement of miR‐205 in the progression of Pten null‐induced prostate cancer. 相似文献
42.
This study is focussed on micro-encapsulation of essential oils in polylactic acid (PLA) and a poly(methyl methacrylate) (PMMA) matrix as well as blends of the same. Microspheres were prepared by the solvent evaporation technique and characterised by scanning electron microscopy (SEM), differential scanning calorimetry (DSC) and Fourier transform infra-red spectroscopy (FTIR). The encapsulation efficiencies and release profiles of the essential oils were studied by gas chromatography mass spectrometry (GC-MS) and head-space solid-phase microextraction GC-MS, respectively. Furthermore, the microspheres were tested for antibacterial activity against both Gram-negative and Gram-positive bacterial strains.
The results showed that the microspheres compositions (PLA/PMMA ratio) have significant effect on their characteristics. The process adopted for preparing the microspheres promoted formation of spherical particles at the sizes of 1.5–9.5?µm. The highest encapsulation efficiency of the prepared microspheres was observed in systems consisting of linalool (81.10?±?10.0?wt. % for PLA system and 76.0?±?3.3?wt. % for PMMA system). Confirmation was also made that the release rate of the microspheres was affected by the size of the same. 相似文献
43.
44.
随着社会的发展,人类生活方式的改变,高血压病越来越高发,具有低龄化趋势,代谢综合征常伴随发生,此种情况下的高血压往往是以舒张压升高为主,临床表现常与“亚健康”状态混淆,未能引起患者甚至部分医生的重视,然而事实上越来越多的科学研究证实舒张压高之危害十分明显,不容忽视。尽管现代医学对舒张压高的病因及病理机制有明确的阐述,但是暂时没有特效的药物。李延教授在治疗高血压病方面有着丰富的临床经验,临床中运用泽泻汤合温胆汤加减治疗舒张压高之眩晕,切中病机,加减灵活,屡有良效。文中从中医角度阐述舒张压高的病因病机,介绍李师辨病辨证思路,组方用药特点,附三则典型验案,另加个人心得体会,以期为舒张压高的有效治疗提供思路。 相似文献
45.
46.
47.
《Foot and Ankle Surgery》2020,26(2):193-197
BackgroundThe aim of this study was to compare the radiographic and functional results between fixation and non-fixation in the Cotton osteotomy for the treatment of adult acquired flatfoot.MethodsA retrospective, case-controlled study of consecutive stage IIB posterior tibial tendon dysfunction (PTTD) patients treated with the same bony reconstructive surgery including cotton osteotomy between 2013 and 2017. Meary’s angle, the medial arch sag angle (MASA), and medial cuneiform cobb angle (MCCA) were evaluated pre-operation, at first weight bearing after surgery, and 12 months post operation.ResultsForty feet were included in the study. The cotton osteotomy utilized screw fixation (n = 20) or non-fixation technique (n = 20). No significant differences between groups were found in pre-operative and follow-up radiographic parameters, union rate, and functional results.ConclusionThe non-fixation with press fit technique is a reliable procedure for Cotton osteotomy and as effective as screw fixation.Level of evidenceLevel III, case control study 相似文献
48.
49.
中药生产过程质量控制关键技术研究进展 总被引:10,自引:8,他引:2
中医药发展已上升到国家战略层面,在医药行业贯彻实施"中国制造2025"战略的新形势下,中药生产过程质量控制是中药工业需要加快突破的关键领域之一。对中药生产过程质量控制领域在工艺设计、分析检测、过程建模、制造装备等方面的关键共性问题进行解析,综述了中药生产过程质量控制体系中工艺过程理解、生产过程实时分析方法开发、过程控制策略建立3个方面的研究进展;并结合企业研究实践,介绍了质量源于设计(quality by design,Qb D)、过程分析技术(process analytical technology,PAT)、实验设计(design of experiment,DOE)、多变量统计分析等关键技术在上述3个研究方向中的应用进展,分析了实际工业应用的难点问题并对其应用前景进行展望,旨在为中药企业应用和提升生产过程质量控制技术提供参考。 相似文献
50.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献